US 10675304
Combination immunotherapies for treatment of cancer
granted A61KA61K2039/5254A61K2039/55588
Quick answer
US patent 10675304 (Combination immunotherapies for treatment of cancer) held by PrimeVax Immuno-Oncology expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- PrimeVax Immuno-Oncology
- Grant date
- Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/5254, A61K2039/55588, A61K2039/585, A61K2039/70